GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Staar Surgical Co (NAS:STAA) » Definitions » Return-on-Tangible-Asset

Staar Surgical Co (Staar Surgical Co) Return-on-Tangible-Asset : -2.73% (As of Mar. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Staar Surgical Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Staar Surgical Co's annualized Net Income for the quarter that ended in Mar. 2024 was $-13.4 Mil. Staar Surgical Co's average total tangible assets for the quarter that ended in Mar. 2024 was $488.8 Mil. Therefore, Staar Surgical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -2.73%.

The historical rank and industry rank for Staar Surgical Co's Return-on-Tangible-Asset or its related term are showing as below:

STAA' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -19.61   Med: 3.44   Max: 10.43
Current: 3.32

During the past 13 years, Staar Surgical Co's highest Return-on-Tangible-Asset was 10.43%. The lowest was -19.61%. And the median was 3.44%.

STAA's Return-on-Tangible-Asset is ranked better than
63.04% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: -2.48 vs STAA: 3.32

Staar Surgical Co Return-on-Tangible-Asset Historical Data

The historical data trend for Staar Surgical Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staar Surgical Co Return-on-Tangible-Asset Chart

Staar Surgical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.58 2.57 9.18 10.43 4.72

Staar Surgical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.60 5.67 4.24 6.49 -2.73

Competitive Comparison of Staar Surgical Co's Return-on-Tangible-Asset

For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staar Surgical Co's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Staar Surgical Co's Return-on-Tangible-Asset falls into.



Staar Surgical Co Return-on-Tangible-Asset Calculation

Staar Surgical Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=21.347/( (416.859+486.906)/ 2 )
=21.347/451.8825
=4.72 %

Staar Surgical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-13.356/( (486.906+490.749)/ 2 )
=-13.356/488.8275
=-2.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Staar Surgical Co  (NAS:STAA) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Staar Surgical Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Staar Surgical Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Staar Surgical Co (Staar Surgical Co) Business Description

Traded in Other Exchanges
Address
25651 Atlantic Ocean Drive, Lake Forest, CA, USA, 92630
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also make lenses which are used in surgery that treats cataracts. The company offers products are ICLs used in refractive surgery and IOLs used in cataract surgery. The company generated sales are from the ophthalmic surgical product segment.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Warren Foust officer: Chief Operating Officer 17 MAGNOLIA DRIVE, LADERA RANCH CA 92694
Magda Michna officer: Chief Clinical, Regulatory, C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618
Keith Holliday officer: V.P., Research & Development 1911 WALKER AVENUE, MONROVIA CA 91016
Robert Studholme officer: Senior VP, Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
James E Francese officer: VP, Global Marketing 1911 WALKER AVE, MONROVIA CA 91016
Caren L Mason director 2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025
Samuel J Gesten officer: VP, General Counsel 1911 WALKER AVENUE, MONROVIA CA 91016
Patrick F. Williams officer: Chief Financial Officer C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Hans-martin Blickensdoerfer officer: VP, International Marketing 1911 WALKER AVENUE, MONROVIA CA 91016
Lou Silverman director
Graydon C. Hansen officer: Sr. VP, Global Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630
Jon K. Hayashida officer: VP, Global Clinical, Medical 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630